Atlas Trials

Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

Clinical trial NCT05651672 · RECRUITING

Trial details

NCT number
NCT05651672
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Gastrointestinal Cancer
Start date
2022-12-02
Primary completion
2024-12-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.